Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.37 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL501357 | 0.76 | UHRF1 (0.39) | — | |
| SCHEMBL7262937 | 0.75 | MAPK1 (0.32) | MAPK1ALDH1A1ALOX15 | |
| SCHEMBL4406050 | 0.75 | ALDH1A1 (0.44) | KIF11MAPK1RAB9AALDH1A1ALOX15 | |
| SCHEMBL5270913 | 0.75 | ESR1 (0.48) | KIF11ALDH1A1ALOX15 | |
| SCHEMBL5208034 | 0.75 | CYP2A6 (0.33) | MAPK1ALDH1A1ALOX15 | |
| SCHEMBL1166696 | 0.74 | AR (0.34) | — | |
| SCHEMBL5312279 | 0.74 | RECQL (0.33) | — | |
| SCHEMBL331282 | 0.74 | NOS3 (0.49) | — | |
| SCHEMBL979053 | 0.72 | ALDH1A1 (0.41) | ALDH1A1 | |
| SCHEMBL480782 | 0.72 | CYP19A1 (0.36) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1841747-B1 | OXAZOLE HYDROXAMIC ACID DERIVATIVES AND USE THEREOF | SK BIOPHARMACEUTICALS CO LTD (KR) | 2012-09-05 | — | — | EP | disclosed |
| US-8039634-B2 | Oxazole hydroxamic acid derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-10-18 | — | — | US | disclosed |
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | IRM LLC (BM) | 2009-10-15 | — | — | US | disclosed |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | SK HOLDINGS CO., LTD | 2009-08-20 | — | — | US | disclosed |
| US-7569593-B2 | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-08-04 | — | — | US | disclosed |
| CN-100455579-C | Compounds and compositions as protein kinase inhibitors | IRM LLC (BM) | 2009-01-28 | — | — | CN | disclosed |
| EP-1670780-A4 | COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-12-17 | — | — | EP | disclosed |
| EP-1042293-B9 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-09-03 | — | — | EP | disclosed |
| US-20080108615-A1 | Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors | SMITHKLINE BEECHAM P.L.C | 2008-05-08 | — | — | US | disclosed |
| EP-1042293-B1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC (US) | 2008-03-19 | — | — | EP | disclosed |
| US-20040127496-A1 | Imidazole-2-carboxamide derivatives as raf kinase inhibitors | DEAN DAVID KENNETH (GB) | 2004-07-01 | — | — | US | disclosed |
| EP-1397354-A1 | IMIDAZOLE-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-17 | — | — | EP | disclosed |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-02-26 | — | — | US | disclosed |
| WO-2003086467-A1 | CANCER TREATMENT METHOD COMPRISING ADMINISTERING AN ERB-FAMILY INHIBITOR AND A RAF AND/OR RAS INHIBITOR | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-23 | — | — | WO | disclosed |
| EP-1318992-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002094808-A1 | IMIDAZOLE-2-CARBOXAMIDE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-11-28 | — | — | WO | disclosed |
| WO-2002024680-A1 | IMIDAZOLE DERIVATIVES AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-03-28 | — | — | WO | disclosed |
| US-6174901-B1 | FOR TREATMENT OF RHEUMATOID ARTHRITIS, PAGETS DISEASE, OSTEOPHOROSIS, MULTIPLE MYELOMA, UVEITITIS, ACUTE OR CHRONIC MYELOGENOUS LEUKEMIA, PANCREATIC .BETA. CELL DESTRUCTION, OSTEOARTHRITIS, RHEUMATOID SPONDYLITIS, GOUTY ARTHRITIS ETC. | AMGEN INC. | 2001-01-16 | — | — | US | disclosed |
| EP-1042293-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | Amgen Inc. (US) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999032448-A1 | SUBSTITUTED PYRIDINE AND PYRIDAZINE COMPOUNDS AND THEIR PHARMACEUTICAL USE | AMGEN INC. (US) | 1999-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258910-A1 | benzo[1,3]dioxol-5-yl-carbamic acid 6-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester and benzo[1,3]dioxol-5-yl-carbamic acid 8-(2-phenyl-5-pyridin-4-yl-1H-imidazol-4-yl)-naphthalen-2-yl ester; | PDGFRA, RAF1, FLT1 | KIF11 543/4885CYP19A1 2544/4885CYP17A1 3663/4885 |
| US-20090209596-A1 | Oxazole Hydroxamic Acid Derivatives and Use Thereof | HDAC1, HDAC5, HDAC7 | KIF11 2906/4885CYP19A1 1623/4885CYP17A1 515/4885 |
| US-20040038964-A1 | Imidazole derivatives as raf kinase inhibitors | BRAF, RAF1, ARAF | KIF11 2188/4885CYP19A1 1965/4885CYP17A1 2548/4885 |
| US-20040127496-A1 | Imidazole-2-carboxamide derivatives as raf kinase inhibitors | RAF1, BRAF, ARAF | KIF11 3793/4885CYP19A1 3497/4885CYP17A1 3925/4885 |
| US-20080108615-A1 | Imidazole-2-Carboxamide Derivatives as Raf Kinase Inhibitors | BRAF, RAF1, ARAF | KIF11 1908/4885CYP19A1 4142/4885CYP17A1 4092/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.